Protein Degradation Leader Nurix Prepares First Clinical Trial

Company Claims Unique Protein Modulation Potential

 
• By Andrew McConaghie
  
San Francisco, California, USA Noe Valley skyline.
Following a successful IPO, San-Francisco-based Nurix is preparing its protein degradation inhibitor for clinical trials.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip